clinical trial · NCT00215813

Ampligen in Chronic Fatigue Syndrome

$AIM →·—·temporarily not available

Chronic Fatigue SyndromePoly I: Poly C12U (Rintatolimod)

brief summary

This is an open label study of Ampligen in patients with chronic fatigue syndrome.

started

—

primary completion

—

completion

—

last updated

Oct 29, 2025

detailed description

An Open-Label Study of Poly I: Poly C12U (Ampligen®) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME). The FDA approved the study for cost recovery. Patients enrolled in the study are responsible for costs related to the therapy, e.g., drug cost, infusion cost, cost of supplies, diagnostic and other laboratory testing.

official title

An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN®) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol